Literature DB >> 3957569

Pharmacokinetic of topical cyclosporin A in the rabbit eye.

M Wiederholt, D Kössendrup, W Schulz, F Hoffmann.   

Abstract

3H labelled cyclosporin A (CS-A) eye drops (2% in castor oil) were applied in rabbits. When a single drop of 10 microliters was given CS-A reached a maximal concentration of 900-1400 ng/ml in the cornea 6 hr after application and then slowly decreased. A substantial level of 600-900 ng/ml was still present after 48 hr. When corneas were analysed for their cellular compartments, 67% of CS-A was found in the epithelium, 25% in the stroma (probably in keratocytes), and 8% in the endothelium. In corneas denervated by circular keratotomy, slightly reduced concentrations were found after surgery, the reduction was not therapeutically significant. Using the HPLC method a significant corneal metabolism of CS-A could be excluded. Scleral concentrations of CS-A as high as 180 ng/ml were found. Concentrations of CS-A in aqueous humor, lens, vitreous body and uvea/retina were below the therapeutic range.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3957569

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  10 in total

1.  Topical treatment of severe corneal ulcers with cyclosporin A.

Authors:  M Zierhut; H J Thiel; E G Weidle; R Waetjen; U Pleyer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

2.  Systemic ciclosporin A in high-risk keratoplasties.

Authors:  T Reinhard; R Sundmacher; P Heering
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-08       Impact factor: 3.117

3.  Liposome-bound cyclosporine: clearance after intravitreal injection.

Authors:  A A Alghadyan; G A Peyman; B Khoobehi; S Milner; K R Liu
Journal:  Int Ophthalmol       Date:  1988       Impact factor: 2.031

4.  Liposome-bound cyclosporine: aqueous and vitreous level after subconjunctival injection.

Authors:  A A Alghadyan; G A Peyman; B Khoobehi; S Milner; K R Liu
Journal:  Int Ophthalmol       Date:  1988       Impact factor: 2.031

5.  Efficacy of topical cyclosporine A 2% in prevention of graft rejection in high-risk keratoplasty: a randomized controlled trial.

Authors:  Rajesh Sinha; Vishal Jhanji; Kamna Verma; Namrata Sharma; Nihar R Biswas; Rasik B Vajpayee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-04-23       Impact factor: 3.117

6.  A compartmental model for the ocular pharmacokinetics of cyclosporine in rabbits.

Authors:  C Oh; B A Saville; Y L Cheng; D S Rootman
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

7.  High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen.

Authors:  Mohammad H Dastjerdi; Pedram Hamrah; Reza Dana
Journal:  Cornea       Date:  2009-12       Impact factor: 2.651

8.  Ocular penetration of cyclosporin A. III: The human eye.

Authors:  D BenEzra; G Maftzir; C de Courten; P Timonen
Journal:  Br J Ophthalmol       Date:  1990-06       Impact factor: 4.638

Review 9.  Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye.

Authors:  Diane D-S Tang-Liu; Andrew Acheampong
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

10.  Short-term Efficacy of Topical Immunosuppressive Agents on the Survival of Cultivated Allo-Conjunctival Equivalents.

Authors:  Young Joo Shin; Mee Kum Kim; Joo Youn Oh; Won Ryang Wee; Jin Hak Lee; Jung Hwa Ko; Hyun Ju Lee; Jae Lim Lee; Byung Moo Min; Young Suk Sohn
Journal:  Korean J Ophthalmol       Date:  2008-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.